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1. Introduction
Skeletal muscle tissue accounts for almost half of the human body mass. Human 
health is markedly affected by any deterioration in the material, metabolic, and 
contractile properties of skeletal muscle. Skeletal muscle is a highly plastic organ 
that is modulated by various pathways controlling cell and protein turnover.
Loss of muscle is a serious consequence of many chronic diseases and of aging 
itself. Muscle loss is also common in muscular dystrophy, in which marked loss of 
various membranous structural proteins occurs around muscle fibers [1]. Defects 
in components of the dystrophin-glycoprotein complex (DGC) are known to be an 
important cause of different muscular dystrophy.
Nowadays, the autophagy-dependent system and ubiquitin-proteasome signal-
ing (UPS) are well known as a major intracellular degradation system, and its 
appropriate function is crucial to health and muscle homeostasis. Indeed, muscle 
wasting and weakness such as cachexia, dystrophy, and sarcopenia is character-
ized by marked decreases in the protein content, muscle fiber size, and muscle 
strength. Interestingly, a functional defect in autophagy-dependent signaling in 
sarcopenic mice and humans was recently suggested [2, 3]. In addition, apparent 
defect of autophagy-dependent signaling is also observed in various muscular 
dystrophies. Indeed, De Palma et al. [4] have described marked defect of autophagy 
in dystrophin-deficient mdx mice and Duchenne muscular dystrophy (DMD) 
patients through the electron microscopic evaluation of muscle tissue and decreased 
autophagic regulator proteins (i.e., Bnip3, Atg12, and LC3-II). The adaptive changes 
of UPS are highly controversial in several muscular dystrophies such as DMD, 
LGMD, and Ullrich congenital muscular dystrophy [5], although UPS seems to not 
be activated in human sarcopenic muscle [6].
2. Various therapeutic approaches for muscle dystrophy
To attenuate various forms of muscular dystrophy, many researchers have 
investigated exercise-based, supplemental, pharmacological, and gene therapy 
approaches. Currently, there is no cure for patients suffering from muscular 
dystrophies. Although several researchers actively try to determine the effect of 
pharmacological inhibition of myostatin for DMD patients, it is heavily difficult to 
obtain positive effects and there are few possibilities for clinical application. Indeed, 
a randomized clinical trial of anti-myostatin for DMD patients had a trend toward 
improved muscle mass and performance, but was stopped early due to non-muscle 
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side effects (i.e., epistaxis and telangiectasias) [7]. Glucocorticoids (GCs) are com-
monly used and still serve as a gold standard therapy, acting as anti-inflammatory 
drugs [8]. More recently, weekly, intermittent GCs treatment has been shown to 
provide a better alternative to a daily regimen without eliciting muscle atrophy [9]. 
Recently, more attention is paid to induced pluripotent stem cells (iPSCs) technol-
ogy and their potential application in DMD treatment [10], although almost all 
studies used DMD model mdx mice. In addition, the strategy using CRISPR/Cas9 
technology progressed dramatically for the restoration of functional dystrophin 
[11]. Young et al. [12] have found that removal of exons 45–55 resulted in the expres-
sion of the stable dystrophin protein in both cardiomyocytes and skeletal myotube 
in vitro. An increasing number of studies report successful and beneficial effects of 
CRISPR/Cas9 only animal models of muscular dystrophy. Thus, it seems to be neces-
sary for substantial time for genome editing tools to apply the dystrophic patients.
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